WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS See full prescribing information for complete boxed warning. Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB).
Interrupt treatment with OLUMIANT if serious infection occurs until the infection is controlled. OLUMIANT should not be given to patients with active TB. Test for latent TB before and during therapy, except for COVID-19; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test.
(5.1) Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase (JAK) inhibitor vs. TNF blockers in rheumatoid arthritis (RA) patients. (5.2) Malignancies have occurred in patients treated with OLUMIANT. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients.
(5.3) Major adverse cardiovascular events (MACE) may occur in patients treated with OLUMIANT. Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients. (5.4) Thrombosis has occurred in patients treated with OLUMIANT. Higher incidence rate of venous thrombosis with OLUMIANT vs.
TNF blockers. Increased incidence rate of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers. (5.5) SERIOUS INFECTIONS Patients treated with OLUMIANT are at risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].
Most patients with rheumatoid arthritis who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. If a serious infection develops, interrupt OLUMIANT until the infection is controlled. Reported infections include: Active tuberculosis, which may present with pulmonary or extrapulmonary disease.
OLUMIANT should not be given to patients with active tuberculosis. Patients, except those with COVID-19, should be tested for latent tuberculosis before initiating OLUMIANT and during therapy. If positive, start treatment for latent infection prior to OLUMIANT use. Invasive fungal infections, including candidiasis and pneumocystosis.
Patients with invasive fungal infections may present with disseminated, rather than localized, disease. Bacterial, viral, and other infections due to opportunistic pathogens. The risks and benefits of treatment with OLUMIANT should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with OLUMIANT including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy [see Warnings and Precautions (5.1)]. MORTALITY In a large, randomized, postmarketing safety study in rheumatoid arthritis (RA) patients 50 years of age and older with at least one cardiovascular risk factor comparing another Janus kinase (JAK) inhibitor to tumor necrosis factor (TNF) blockers, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed with the JAK inhibitor [see Warnings and Precautions (5.2)].
MALIGNANCIES Lymphoma and other malignancies have been observed in patients treated with OLUMIANT. In RA patients treated with another JAK inhibitor, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed when compared with TNF blockers. Patients who are current or past smokers are at additional increased risk [see Warnings and Precautions (5.3)].
MAJOR ADVERSE CARDIOVASCULAR EVENTS MACE (defined as cardiovascular death, myocardial infarction, and stroke) may occur in patients treated with OLUMIANT. In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of MACE was observed when compared with TNF blockers.
Patients who are current or past smokers are at additional increased risk. Discontinue OLUMIANT in patients that have experienced a myocardial infarction or stroke [see Warnings and Precautions (5.4)]. THROMBOSIS Thrombosis, including deep venous thrombosis and pulmonary embolism, has been observed at an increased incidence in patients treated with OLUMIANT compared to placebo.
In addition, there were cases of arterial thrombosis. Many of these adverse events were serious and some resulted in death. In two studies of patients with RA with an increased risk of venous thrombosis, a higher rate of venous thrombosis was observed in patients treated with OLUMIANT compared to patients treated with TNF blockers.
In RA patients 50 years of age and older with at least one cardiovascular risk factor treated with another JAK inhibitor, a higher rate of thrombosis was observed when compared with TNF blockers. Avoid OLUMIANT in patients at risk. Patients with symptoms of thrombosis should discontinue OLUMIANT and be promptly evaluated. [see Warnings and Precautions (5.5)].
Use: Labeled indications
- Moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response to one or more TNF blockers.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for the treatment of: Moderately to severely active rheumatoid arthritis (RA) in adults who have had an inadequate response to one or more TNF blockers. (1.1) Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine.
(1.1) COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. (1.2) Severe alopecia areata (AA) in adults and pediatric patients 12 years of age and older. (1.3) Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
(1.3) 1.1 Moderately to Severely Active Rheumatoid Arthritis OLUMIANT ® is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers. Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine. 1.2 Coronavirus Disease 2019 (COVID-19) OLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). 1.3 Severe Alopecia Areata OLUMIANT is indicated for the treatment of severe alopecia areata in adults and pediatric patients 12 years of age and older.
Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.
Contraindications
4 CONTRAINDICATIONS None. None.
US FDA labelDosing: Adult
- Administration Instructions: See the full prescribing information for recommended evaluations and immunizations prior to OLUMIANT treatment. (2.1)
- Moderately to Severely Active RA and Severe AA: Avoid initiation or interrupt OLUMIANT in patients with anemia (hemoglobin <8 g/dL), lymphopenia (ALC <500 cells/mm 3) or neutropenia (ANC <1000 cells/mm 3). (2.1, 2.5, 5.9)
- COVID-19: Avoid initiation or interrupt OLUMIANT in patients with lymphopenia (ALC <200 cells/mm 3) or neutropenia (ANC <500 cells/mm 3). (2.1, 2.5, 5.9)
- Recommended Dosage: Moderately to Severely Active RA: 2 mg once daily. OLUMIANT may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs. (2.2)
- COVID-19: 4 mg once daily for up to 14 days. (2.3)
- Severe Alopecia Areata (2.4): 2 mg once daily. Increase to 4 mg once daily, if the response to treatment is not adequate. For patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4 mg once daily. Reduce the dosage to 2 mg once daily when an adequate response has been achieved. Dosage Modifications in Patients with Renal or Hepatic Impairment, or Cytopenias See the full prescribing information for dosage modifications by indication. (2.5, 2.6, 5.9)
2.1 Recommended Evaluations and Immunization Prior to Treatment Initiation
2.1 Recommended Evaluations and Immunization Prior to Treatment Initiation Prior to OLUMIANT treatment initiation, consider performing the following evaluations: Active and latent tuberculosis (TB) infection evaluation – OLUMIANT should not be given to patients with active tuberculosis (TB). If latent infection is positive in patients with moderately to severely active rheumatoid arthritis or severe alopecia areata, consider treatment for TB prior to OLUMIANT use [see Warnings and Precautions (5.1)].
Viral hepatitis screening in accordance with clinical guidelines [see Warnings and Precautions (5.1)]. Complete blood count – Assess baseline values and verify whether treatment can be initiated: In patients with moderately to severely active rheumatoid arthritis or severe alopecia areata, OLUMIANT initiation is not recommended in patients with an absolute lymphocyte count (ALC) <500 cells/μl, absolute neutrophil count (ANC) <1000 cells/μl, or hemoglobin level <8 g/dL.
In patients with COVID-19, OLUMIANT initiation is not recommended if the ALC is <200 cells/μl or if the ANC is <500 cells/μl. Monitor complete blood counts during treatment and modify dosage as recommended [see Dosage and Administration (2.5) and Warnings and Precautions (5.9)]. Baseline hepatic and renal function – Assess baseline values and monitor patients for laboratory changes.
Modify dosage based on hepatic and renal impairment, and laboratory abnormalities [see Dosage and Administration (2.6) and Warnings and Precautions (5.9)]. In patients with moderately to severely active rheumatoid arthritis or severe alopecia areata, update immunizations in agreement with current immunization guidelines [see Warnings and Precautions (5.10)].
2.2 Dosage Recommendations in Moderately to Severely Active Rheumatoid Arthritis
2.2 Dosage Recommendations in Moderately to Severely Active Rheumatoid Arthritis The recommended dosage of OLUMIANT is 2 mg once daily orally, with or without food [see Clinical Pharmacology (12.3)]. An alternative administration for patients unable to swallow tablets may be used [see Dosage and Administration (2.8)]. OLUMIANT may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.
2.3 Dosage Recommendations
2.3 Dosage Recommendations in COVID-19 The recommended dosage of OLUMIANT for adults is 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first. An alternative administration for patients unable to swallow tablets may be used [see Dosage and Administration (2.8)].
2.4 Dosage Recommendations in Severe Alopecia Areata
2.4 Dosage Recommendations in Severe Alopecia Areata The recommended dosage of OLUMIANT for adults and pediatric patients 12 years of age and older is 2 mg once daily orally, with or without food. Increase to 4 mg once daily if the response to treatment is not adequate. For adults and pediatric patients 12 years of age and older with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4 mg once daily, with or without food.
Once patients achieve an adequate response to treatment with 4 mg, decrease the dosage to 2 mg once daily.
2.5 Dosage Modifications Due to Infections, Cytopenias and Anemia Moderately to Severely…
2.5 Dosage Modifications Due to Infections, Cytopenias and Anemia Moderately to Severely Active Rheumatoid Arthritis and Severe Alopecia Areata Avoid use of OLUMIANT in patients with active, serious or opportunistic infection, including localized infections. If a patient develops a serious infection hold treatment with OLUMIANT until the infection is controlled [see Warnings and Precautions (5.1)].
Dosage modifications for patients with moderately to severely active rheumatoid arthritis or severe alopecia areata and cytopenias or anemia are described in Table 1. Table 1: Dosage Modifications for Cytopenias and Anemia in Patients with Moderately to Severely Active Rheumatoid Arthritis or Severe Alopecia Areata Laboratory Analyte Laboratory Analyte Value Recommendation Absolute Lymphocyte Count (ALC) ≥500 cells/μL Maintain dosage <500 cells/μL Interrupt OLUMIANT until ALC ≥500 cells/μL Absolute Neutrophil Count (ANC) ≥1000 cells/μL Maintain dosage <1000 cells/μL Interrupt OLUMIANT until ANC ≥1000 cells/μL Hemoglobin ≥8 g/dL Maintain dosage <8 g/dL Interrupt OLUMIANT until hemoglobin ≥8 g/dL COVID-19 Monitor patients for signs and symptoms of new infections during treatment with OLUMIANT.
The risks and benefits of treatment with OLUMIANT in COVID-19 patients with other concurrent infections should be considered [see Warnings and Precautions (5.1)]. Dosage modifications for patients with COVID-19 and cytopenias are described in Table 2. Table 2: Dosage Modifications for Cytopenias in Patients with COVID-19 Laboratory Analyte Laboratory Analyte Value Recommendation Absolute Lymphocyte Count (ALC) ≥200 cells/μL Maintain dosage <200 cells/μL Interrupt OLUMIANT until ALC ≥200 cells/μL Absolute Neutrophil Count (ANC) ≥500 cells/μL Maintain dosage <500 cells/μL Interrupt OLUMIANT until ANC ≥500 cells/μL
2.6 Dosage Modifications for Patients with Renal Impairment or Hepatic
2.6 Dosage Modifications for Patients with Renal Impairment or Hepatic Impairment Moderately to Severely Active Rheumatoid Arthritis Renal Impairment Dosage modifications for patients with rheumatoid arthritis and renal impairment are described in Table 3. Table 3: Dosage Modifications for Patients with Moderately to Severely Active Rheumatoid Arthritis and Renal Impairment Renal Impairment Stage Estimated Glomerular Filtration Rate (eGFR) Recommendation Mild 60 - <90 mL/minute/1.73 m² 2 mg once daily Moderate 30 - <60 mL/min/1.73 m² 1 mg once daily Severe <30 mL/minute/1.73 m² Not recommended Hepatic Impairment OLUMIANT is not recommended for use in patients with severe (Child-Pugh C) hepatic impairment.
No dose adjustment of OLUMIANT is necessary in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Interrupt OLUMIANT, if increases in ALT or AST are observed and drug-induced liver injury (DILI) is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.9)]. COVID-19 Renal Impairment Dosage modifications for patients with COVID-19 and renal impairment are described in Table 4.
Table 4: Dosage Modifications for Patients with COVID-19 and Renal Impairment Renal Impairment Stage Estimated Glomerular Filtration Rate (eGFR) Recommendation Mild 60 - <90 mL/min/1.73 m² 4 mg once daily Moderate 30 - <60 mL/min/1.73 m² 2 mg once daily Severe 15 - <30 mL/min/1.73 m² 1 mg once daily End Stage Renal Disease, Patients on Dialysis, or Acute Kidney Injury <15 mL/min/1.73 m² Not recommended Hepatic Impairment It is not known if dosage adjustment is needed in patients with COVID-19 and severe (Child-Pugh C) hepatic impairment. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk.
No dose adjustment of OLUMIANT is necessary in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Interrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.9)]. Severe Alopecia Areata Renal Impairment Dosage modifications for patients with severe alopecia areata and renal impairment are described in Table 5.
Table 5: Dosage Modifications for Patients with Severe Alopecia Areata and Renal Impairment Renal Impairment Stage Estimated Glomerular Filtration Rate (eGFR) Recommendation If the recommended dosage is 2 mg once daily If the recommended dosage is 4 mg once daily Mild 60 – <90 mL/minute/1.73 m² Maintain dosage Moderate 30 – <60 mL/min/1.73 m² Reduce to 1 mg once daily Reduce to 2 mg once daily Severe <30 mL/minute/1.73 m² Not recommended Hepatic Impairment OLUMIANT is not recommended for use in patients with severe (Child-Pugh C) hepatic impairment. No dose adjustment of OLUMIANT is necessary in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment.
Interrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.9)].
2.7 Dosage Modifications Due to Drug Interactions Moderately to Severely Active Rheumatoid…
2.7 Dosage Modifications Due to Drug Interactions Moderately to Severely Active Rheumatoid Arthritis, COVID-19 or Severe Alopecia Areata The recommended dosage of OLUMIANT in patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors, such as probenecid, are shown in Table 6 [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)]. Table 6: Dosage Modifications when Coadministered with Strong OAT3 Inhibitors in Patients with Moderately to Severely Active Rheumatoid Arthritis, COVID-19 or Severe Alopecia Areata Concomitant Medication Recommendation Strong OAT3 inhibitors (e.g., probenecid) If the recommended dosage is 4 mg once daily, reduce dosage to 2 mg once daily.
If the recommended dosage is 2 mg once daily, reduce dosage to 1 mg once daily. If the recommended dosage is 1 mg once daily, consider discontinuing probenecid.
2.8 Alternative Administration for Patients Unable
2.8 Alternative Administration for Patients Unable to Swallow Tablets For patients who are unable to swallow whole tablets, an alternative mode of administration may be considered: Oral dispersion Gastrostomy tube (G tube) Nasogastric tube (NG tube) or orogastric tube (OG tube) Intact tablets are not hazardous. Tablets may be crushed to facilitate dispersion.
It is not known if powder from the crushed tablets may constitute a reproductive hazard to the preparer. If tablets are crushed, use proper control measures (e.g., ventilated enclosure) or personal protective equipment (i.e., N95 respirator). Dispersed tablets are stable in water for up to 4 hours. Preparation Instructions for Alternative Administration: Oral administration of dispersed tablets in water: For patients who are unable to swallow whole tablets, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 10 mL (5 mL minimum) of room temperature water, dispersed by gently swirling the tablet(s) and immediately taken orally.
The container should be rinsed with an additional 10 mL (5 mL minimum) of room temperature water and the entire contents swallowed by the patient (Table 7). Administration via G tube: For patients with a G tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 15 mL (10 mL minimum) of room temperature water and dispersed with gentle swirling.
Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw entire contents from the container into an appropriate syringe and immediately administer through the gastric feeding tube. Rinse container with approximately 15 mL (10 mL minimum) of room temperature water, withdraw the contents into the syringe, and administer through the tube (Table 7).
Administration via NG or OG tube: For patients with a NG or OG tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or a combination of tablets necessary to achieve the desired dose up to 4-mg may be placed into a container with approximately 30 mL of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe.
Withdraw the entire contents from the container into an appropriate syringe and immediately administer through the enteral feeding tube. To avoid clogging of small diameter tubes (smaller than 12 Fr), the syringe can be held horizontally and shaken during administration. Rinse container with a sufficient amount (minimum of 15 mL) of room temperature water, withdraw the contents into the syringe, and administer through the tube (Table 7).
Table 7: Dispersion and Rinse Volume for Alternative Administration Administration via Dispersion Volume Container Rinse Volume Oral dispersion 10 mL 10 mL G tube 15 mL 15 mL NG tube or OG tube 30 mL 15 mL
Dosing: Altered kidney function
2.6 Dosage Modifications for Patients with Renal Impairment or Hepatic Impairment Moderately to Severely Active Rheumatoid Arthritis Renal Impairment Dosage modifications for patients with rheumatoid arthritis and renal impairment are described in Table 3. Table 3: Dosage Modifications for Patients with Moderately to Severely Active Rheumatoid Arthritis and Renal Impairment Renal Impairment Stage Estimated Glomerular Filtration Rate (eGFR) Recommendation Mild 60 - <90 mL/minute/1.73 m² 2 mg once daily Moderate 30 - <60 mL/min/1.73 m² 1 mg once daily Severe <30 mL/minute/1.73 m² Not recommended Hepatic Impairment OLUMIANT is not recommended for use in patients with severe (Child-Pugh C) hepatic impairment.
No dose adjustment of OLUMIANT is necessary in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Interrupt OLUMIANT, if increases in ALT or AST are observed and drug-induced liver injury (DILI) is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.9)]. COVID-19 Renal Impairment Dosage modifications for patients with COVID-19 and renal impairment are described in Table 4.
Table 4: Dosage Modifications for Patients with COVID-19 and Renal Impairment Renal Impairment Stage Estimated Glomerular Filtration Rate (eGFR) Recommendation Mild 60 - <90 mL/min/1.73 m² 4 mg once daily Moderate 30 - <60 mL/min/1.73 m² 2 mg once daily Severe 15 - <30 mL/min/1.73 m² 1 mg once daily End Stage Renal Disease, Patients on Dialysis, or Acute Kidney Injury <15 mL/min/1.73 m² Not recommended Hepatic Impairment It is not known if dosage adjustment is needed in patients with COVID-19 and severe (Child-Pugh C) hepatic impairment. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk.
No dose adjustment of OLUMIANT is necessary in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Interrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.9)]. Severe Alopecia Areata Renal Impairment Dosage modifications for patients with severe alopecia areata and renal impairment are described in Table 5.
Table 5: Dosage Modifications for Patients with Severe Alopecia Areata and Renal Impairment Renal Impairment Stage Estimated Glomerular Filtration Rate (eGFR) Recommendation If the recommended dosage is 2 mg once daily If the recommended dosage is 4 mg once daily Mild 60 – <90 mL/minute/1.73 m² Maintain dosage Moderate 30 – <60 mL/min/1.73 m² Reduce to 1 mg once daily Reduce to 2 mg once daily Severe <30 mL/minute/1.73 m² Not recommended Hepatic Impairment OLUMIANT is not recommended for use in patients with severe (Child-Pugh C) hepatic impairment. No dose adjustment of OLUMIANT is necessary in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment.
Interrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.9)].
8.7 Renal Impairment Renal function was found to significantly affect baricitinib exposure. Moderately to Severely Active Rheumatoid Arthritis and Severe Alopecia Areata – The recommended dosage of OLUMIANT in patients with moderate renal impairment (estimated glomerular filtration rate (GFR) between 30 and <60 mL/min/1.73 m²) should be reduced by half the recommended dose.
OLUMIANT is not recommended for use in patients with moderately to severely active rheumatoid arthritis or severe alopecia areata and severe renal impairment (estimated GFR of less than 30 mL/min/1.73 m²) [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)]. COVID-19 – The recommended dosage of OLUMIANT in patients with moderate renal impairment (estimated GFR between 30 and <60 mL/min/1.73 m²) or severe renal impairment (estimated GFR between 15 and <30 mL/min/1.73 m²) is 2 mg once daily and 1 mg once daily, respectively.
OLUMIANT is not recommended for use in patients who are on dialysis, have end-stage renal disease (ESRD), or with estimated GFR of <15 mL/min/1.73 m² [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)].
Patients with Renal Impairment Baricitinib systemic exposure in AUC was increased by 1.41-, 2.22-, 4.05- and 2.41-fold for mild (60 – <90 mL/minute/1.73 m²), moderate (30 – <60 mL/min/1.73 m²), severe (<30 mL/minute/1.73 m²), and ESRD (with hemodialysis) renal impairment sub-groups, respectively, compared to subjects with normal renal function. The corresponding values for increase in C max were 1.16-, 1.46-, 1.40- and 0.88-fold, respectively (Figure 1) [see Use in Specific Populations (8.7)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.6 Hepatic Impairment No dose adjustment is necessary in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. The use of OLUMIANT has not been studied in patients with moderately to severely active rheumatoid arthritis or severe alopecia areata and severe (Child-Pugh C) hepatic impairment and is therefore not recommended.
OLUMIANT has not been studied in patients with COVID-19 and severe hepatic impairment. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)].
2.6 Dosage Modifications for Patients with Renal Impairment or Hepatic Impairment Moderately to Severely Active Rheumatoid Arthritis Renal Impairment Dosage modifications for patients with rheumatoid arthritis and renal impairment are described in Table 3. Table 3: Dosage Modifications for Patients with Moderately to Severely Active Rheumatoid Arthritis and Renal Impairment Renal Impairment Stage Estimated Glomerular Filtration Rate (eGFR) Recommendation Mild 60 - <90 mL/minute/1.73 m² 2 mg once daily Moderate 30 - <60 mL/min/1.73 m² 1 mg once daily Severe <30 mL/minute/1.73 m² Not recommended Hepatic Impairment OLUMIANT is not recommended for use in patients with severe (Child-Pugh C) hepatic impairment.
No dose adjustment of OLUMIANT is necessary in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Interrupt OLUMIANT, if increases in ALT or AST are observed and drug-induced liver injury (DILI) is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.9)]. COVID-19 Renal Impairment Dosage modifications for patients with COVID-19 and renal impairment are described in Table 4.
Table 4: Dosage Modifications for Patients with COVID-19 and Renal Impairment Renal Impairment Stage Estimated Glomerular Filtration Rate (eGFR) Recommendation Mild 60 - <90 mL/min/1.73 m² 4 mg once daily Moderate 30 - <60 mL/min/1.73 m² 2 mg once daily Severe 15 - <30 mL/min/1.73 m² 1 mg once daily End Stage Renal Disease, Patients on Dialysis, or Acute Kidney Injury <15 mL/min/1.73 m² Not recommended Hepatic Impairment It is not known if dosage adjustment is needed in patients with COVID-19 and severe (Child-Pugh C) hepatic impairment. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk.
No dose adjustment of OLUMIANT is necessary in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Interrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.9)]. Severe Alopecia Areata Renal Impairment Dosage modifications for patients with severe alopecia areata and renal impairment are described in Table 5.
Table 5: Dosage Modifications for Patients with Severe Alopecia Areata and Renal Impairment Renal Impairment Stage Estimated Glomerular Filtration Rate (eGFR) Recommendation If the recommended dosage is 2 mg once daily If the recommended dosage is 4 mg once daily Mild 60 – <90 mL/minute/1.73 m² Maintain dosage Moderate 30 – <60 mL/min/1.73 m² Reduce to 1 mg once daily Reduce to 2 mg once daily Severe <30 mL/minute/1.73 m² Not recommended Hepatic Impairment OLUMIANT is not recommended for use in patients with severe (Child-Pugh C) hepatic impairment. No dose adjustment of OLUMIANT is necessary in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment.
Interrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.9)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of OLUMIANT for the treatment of severe alopecia areata have been established in pediatric patients 12 years of age and older. Use of OLUMIANT for this indication is supported by evidence from an adequate and well-controlled trial that included a total of 316 pediatric subjects 12 years of age and older weighing at least 30 kg who were exposed to OLUMIANT for at least one year.
Overall, the safety profile observed in pediatric patients 12 years of age and older with severe alopecia areata treated with OLUMIANT is consistent with the safety profile in adults with severe alopecia areata [see Adverse Reactions (6.1), Pharmacokinetics (12.3), Clinical Studies (14.3)]. The safety and effectiveness of OLUMIANT for the treatment of severe alopecia areata have not been established in pediatric patients younger than 12 years of age.
The safety and effectiveness of OLUMIANT for the treatment of juvenile idiopathic arthritis or COVID-19 have not been established in pediatric patients.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the 3100 subjects treated in the moderately to severely active rheumatoid arthritis clinical trials, a total of 537 subjects were 65 years of age and older, including 71 subjects 75 years of age and older. Of the 2558 subjects treated in the COVID-19 clinical trials, a total of 791 were 65 years of age and older, including 295 subjects 75 years and older.
No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3)]. Of the 1200 subjects in the severe alopecia areata clinical trials, a total of 29 subjects were 65 years of age or older.
The number of subjects aged 65 years and older was not sufficient to determine whether they respond differently from younger subjects. OLUMIANT is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because geriatric patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.6)].
Administration
2.8 Alternative Administration for Patients Unable to Swallow Tablets For patients who are unable to swallow whole tablets, an alternative mode of administration may be considered: Oral dispersion Gastrostomy tube (G tube) Nasogastric tube (NG tube) or orogastric tube (OG tube) Intact tablets are not hazardous. Tablets may be crushed to facilitate dispersion. It is not known if powder from the crushed tablets may constitute a reproductive hazard to the preparer. If tablets are crushed, use proper control measures (e.g., ventilated enclosure) or personal protective equipment (i.e., N95 respirator). Dispersed tablets are stable in water for up to 4 hours. Preparation Instructions for Alternative Administration : Oral administration of dispersed tablets in water: For patients who are unable to swallow whole tablets, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 10 mL (5 mL minimum) of room temperature water, dispersed by gently swirling the tablet(s) and immediately taken orally. The container should be rinsed with an additional 10 mL (5 mL minimum) of room temperature water and the entire contents swallowed by the patient ( Table 7 ). Administration via G tube: For patients with a G tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 15 mL (10 mL minimum) of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw entire contents from the container into an appropriate syringe and immediately administer through the gastric feeding tube. Rinse container with approximately 15 mL (10 mL minimum) of room temperature water, withdraw the contents into the syringe, and administer through the tube ( Table 7 ). Administration via NG or OG tube: For patients with a NG or OG tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or a combination of tablets necessary to achieve the desired dose up to 4-mg may be placed into a container with approximately 30 mL of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw the entire contents from the container into an appropriate syringe and immediately administer through the enteral feeding tube. To avoid clogging of small diameter tubes (smaller than 12 Fr), the syringe can be held horizontally and shaken during administration. Rinse container with a sufficient amount (minimum of 15 mL) of room temperature water, withdraw the contents into the syringe, and administer through the tube ( Table 7 ). Table 7: Dispersion and Rinse Volume for Alternative Administration Administration via Dispersion Volume Container Rinse Volume Oral dispersion 10 mL 10 mL G tube 15 mL 15 mL NG tube or OG tube 30 mL 15 mL
US FDA labelDosage forms
Philippines
- Film-coated tablet: 2 mg, 4 mg
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Baricitinib as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
OlumiantBaricitinib | 2mg Film-Coated TabletCold formable aluminium foil with aluminium foil lidding blister pack x 7's (Box of 7's, 14's and 28's); Physician's sample: Cold formable aluminum foil with aluminum foil lidding blister pack x 7's (Box of 28's) | Rx | Lilly del Caribe Inc.United States | Importer: Zuellig Pharma CorporationTrader: Lilly S.A. | DR-XY46772 | Oct 26, 2029 | |
OlumiantBaricitinib | 4 mg Film-Coated TabletCold formable aluminium foil with aluminium foil lidding blister pack x 7's (Box of 7's, 14's and 28's); Physician's sample: Cold formable aluminium foil with aluminium foil lidding blister pack x 7's (Box of 28's) | Rx | Lilly Del Caribe, Inc.United States | Zuellig Pharma Corporation | DR-XY46773 | Oct 18, 2031 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS OLUMIANT is available as debossed, film-coated tablets: 1 mg tablet contains a recessed area on each face of the tablet surface, is very light pink, round, debossed with “Lilly” on one side and “1” on the other. 2 mg tablet contains a recessed area on each face of the tablet surface, is light pink, oblong, debossed with “Lilly” on one side and “2” on the other. 4 mg tablet contains a recessed area on each face of the tablet surface, is medium pink, round, debossed with “Lilly” on one side and “4” on the other. Tablets: 1 mg, 2 mg, 4 mg (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- Hypersensitivity Reactions: Discontinue OLUMIANT if a serious hypersensitivity reaction occurs. (5.6)
- Gastrointestinal Perforations: Monitor patients who may be at increased risk and evaluate promptly new onset of abdominal symptoms. (5.7)
- Hypoglycemia in Patients with Diabetes: Consider increased monitoring of blood glucose; advise patients with diabetes to notify their healthcare provider if they develop signs or symptoms of hypoglycemia. (5.8)
- Laboratory Abnormalities: Monitor for changes in lymphocytes, neutrophils, hemoglobin, liver enzymes, and lipids. (5.9)
- Vaccinations: Avoid use with live vaccines. (5.10)
5.1 Serious Infections
5.1 Serious Infections Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving OLUMIANT. The most common serious infections reported with OLUMIANT included pneumonia, herpes zoster, and urinary tract infection [see Adverse Reactions (6.1)].
Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus were reported with OLUMIANT. Some patients have presented with disseminated rather than localized disease, and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Avoid use of OLUMIANT in patients with an active, serious infection, including localized infections. Consider the risks and benefits of treatment prior to initiating OLUMIANT in patients: with chronic or recurrent infection who have been exposed to tuberculosis with a history of a serious or an opportunistic infection who have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or with underlying conditions that may predispose them to infection.
In patients with rheumatoid arthritis or alopecia areata, closely monitor for the development of signs and symptoms of infection during and after treatment with OLUMIANT. Interrupt OLUMIANT in patients with rheumatoid arthritis or alopecia areata, if the patient develops a serious infection, an opportunistic infection, or sepsis.
A patient who develops a new infection during treatment with OLUMIANT should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be initiated, the patient should be closely monitored, and OLUMIANT should be interrupted if the patient is not responding to therapy. Do not resume OLUMIANT until the infection is controlled.
In patients with COVID-19, monitor for signs and symptoms of new infections during and after treatment with OLUMIANT. There is limited information regarding the use of OLUMIANT in patients with COVID-19 and concomitant active serious infections. The risks and benefits of treatment with OLUMIANT in COVID-19 patients with other concurrent infections should be considered.
Tuberculosis Evaluate patients for active infection prior to administration of OLUMIANT. OLUMIANT should not be given to patients with active TB. Test patients with rheumatoid arthritis or alopecia areata for latent tuberculosis. Patients with rheumatoid arthritis or alopecia areata and latent tuberculosis (TB) should be treated with standard antimycobacterial therapy before initiating OLUMIANT.
Consider anti-TB therapy prior to initiation of OLUMIANT in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection. Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient.
During OLUMIANT use, monitor patients for the development of signs and symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy. Viral Reactivation Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies with OLUMIANT.
If a patient develops herpes zoster, interrupt OLUMIANT treatment until the episode resolves. The impact of OLUMIANT on chronic viral hepatitis reactivation is unknown. Patients with evidence of active hepatitis B or C infection were excluded from clinical trials. In clinical trials in patients with rheumatoid arthritis or alopecia areata, patients who were positive for hepatitis C antibody but negative for hepatitis C virus RNA were permitted to enroll.
Patients with positive hepatitis B surface antibody and hepatitis B core antibody, without hepatitis B surface antigen, were permitted to enroll; such patients should be monitored for expression of hepatitis B virus (HBV) DNA. Should HBV DNA be detected, consult with a hepatologist. Perform screening for viral hepatitis in accordance with clinical guidelines before starting therapy with OLUMIANT.
5.2 Mortality
5.2 Mortality In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed in patients treated with the JAK inhibitor compared with TNF blockers. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT.
5.3 Malignancy and Lymphoproliferative Disorders
5.3 Malignancy and Lymphoproliferative Disorders Malignancies were observed in clinical studies of OLUMIANT [see Adverse Reactions (6.1)]. In the integrated analysis of two randomized controlled studies (RA Safety Studies 1 and 2) [see Clinical Studies (14.4)], the incidence rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was 1.06 per 100 patient-years in subjects treated with OLUMIANT 2 mg/day and 4 mg/day combined, and 0.83 per 100 patient-years in subjects treated with TNF blockers.
In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers.
A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. In this study, current or past smokers had an additional increased risk of overall malignancies. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT, particularly in patients with a known malignancy (other than successfully treated NMSC), patients who develop a malignancy, and patients who are current or past smokers.
Non-melanoma skin cancers Non-melanoma skin cancers (NMSCs) have been reported in patients treated with OLUMIANT. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.
5.4 Major Adverse Cardiovascular Events
5.4 Major Adverse Cardiovascular Events Major adverse cardiovascular events (MACE) may occur in patients treated with OLUMIANT. In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of MACE defined as cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke was observed with the JAK inhibitor compared to those treated with TNF blockers.
Patients who are current or past smokers are at additional increased risk. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur.
Discontinue OLUMIANT in patients that have experienced a myocardial infarction or stroke.
5.5 Thrombosis
5.5 Thrombosis Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), was observed at an increased incidence in patients treated with OLUMIANT compared to patients treated with placebo. In addition, arterial thrombosis events in the extremities have been reported in clinical studies in patients treated with OLUMIANT.
Many of these adverse events were serious and some resulted in death. In a planned integrated analysis of two randomized controlled studies (RA Safety Studies 1 and 2) in RA subjects with increased risk of venous thromboembolic events (VTE), a higher incidence rate of VTE, including DVT and PE, was observed in subjects treated with OLUMIANT 2 mg/day or OLUMIANT 4 mg/day compared to those treated with TNF blockers [see Clinical Studies (14.4)].
In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of overall thrombosis, DVT, and PE were observed compared to those treated with TNF blockers. If clinical features of DVT/PE or arterial thrombosis occur, patients should discontinue OLUMIANT and be evaluated promptly and treated appropriately.
Avoid OLUMIANT in patients that may be at increased risk of thrombosis.
5.6 Hypersensitivity Reactions
5.6 Hypersensitivity Reactions Reactions such as angioedema, urticaria, and rash that may reflect drug hypersensitivity have been observed in patients receiving OLUMIANT, including serious reactions. If a serious hypersensitivity reaction occurs, promptly discontinue OLUMIANT while evaluating the potential causes of the reaction [see Adverse Reactions (6.2)].
5.7 Gastrointestinal Perforations
5.7 Gastrointestinal Perforations Gastrointestinal perforations have been reported in clinical studies with OLUMIANT. Monitor OLUMIANT-treated patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis). Evaluate promptly patients presenting with new onset abdominal symptoms for early identification of gastrointestinal perforation.
5.8 Hypoglycemia in Patients with Diabetes
5.8 Hypoglycemia in Patients with Diabetes Hypoglycemia, including severe hypoglycemia, has been reported following initiation of OLUMIANT and other JAK inhibitors in patients with diabetes. During treatment with OLUMIANT, consider increased monitoring of blood glucose as clinically indicated in patients with diabetes. Advise patients with diabetes to notify their healthcare provider if they develop signs or symptoms of hypoglycemia.
5.9 Laboratory Abnormalities Neutropenia
5.9 Laboratory Abnormalities Neutropenia – Treatment with OLUMIANT was associated with an increased incidence of neutropenia (ANC less than 1000 cells/mm 3) compared to placebo. In patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with an ANC less than 1000 cells/mm 3.
In patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with ANC less than 1000 cells/mm 3. Avoid initiation or interrupt OLUMIANT treatment in patients with COVID-19 and an ANC less than 500 cells/mm 3. Evaluate at baseline and thereafter according to routine patient management. Adjust dosing based on ANC [see Dosage and Administration (2.1, 2.5) and Adverse Reactions (6.1)].
Lymphopenia – ALC less than 500 cells/mm 3 were reported in OLUMIANT clinical trials. Lymphocyte counts less than the lower limit of normal were associated with infection in patients treated with OLUMIANT, but not placebo. In patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with an ALC less than 500 cells/mm 3.
In patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with ALC less than 200 cells/mm 3. Avoid initiation or interrupt OLUMIANT treatment in patients with COVID-19 and an ALC less than 200 cells/mm 3. Evaluate at baseline and thereafter according to routine patient management. Adjust dosing based on ALC [see Dosage and Administration (2.1, 2.5)].
Anemia – Decreases in hemoglobin levels to less than 8 g/dL were reported in OLUMIANT clinical trials. In patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with hemoglobin less than 8 g/dL. Evaluate at baseline and thereafter according to routine patient management.
Adjust dosing based on hemoglobin levels [see Dosage and Administration (2.1, 2.5)]. In patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with hemoglobin less than 8 g/dL. Liver Enzyme Elevations – Treatment with OLUMIANT was associated with increased incidence of liver enzyme elevation compared to placebo.
Increases of ALT ≥5 times the upper limit of normal (ULN) and increases of AST ≥10 times the ULN were observed in patients in OLUMIANT clinical trials. Evaluate at baseline and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury.
If increases in ALT or AST are observed and drug-induced liver injury is suspected, interrupt OLUMIANT until this diagnosis is excluded [see Adverse Reactions (6.1)]. Lipid Elevations – Treatment with OLUMIANT was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol.
Assessment of lipid parameters should be performed approximately 12 weeks following OLUMIANT initiation in patients with rheumatoid arthritis or alopecia areata [see Adverse Reactions (6.1)]. Manage patients according to clinical guidelines for the management of hyperlipidemia.
5.10 Vaccinations
5.10 Vaccinations Avoid use of live vaccines with OLUMIANT. Update immunizations in patients with rheumatoid arthritis or alopecia areata prior to initiating OLUMIANT therapy in agreement with current immunization guidelines.
Drug interactions
In patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors (e.g., probenecid), reduce the recommended OLUMIANT dosage. (2.7, 7.1)
7.1 Strong OAT3 Inhibitors
7.1 Strong OAT3 Inhibitors Baricitinib exposure is increased when OLUMIANT is co-administered with strong OAT3 inhibitors (such as probenecid), hence the dosage of baricitinib should be reduced by half the recommended dose [see Dosage and Administration (2.7) and Clinical Pharmacology (12.3)].
7.2 Other JAK Inhibitors or Biologic DMARDs
7.2 Other JAK Inhibitors or Biologic DMARDs OLUMIANT has not been studied in combination with other JAK inhibitors or with biologic DMARDs [see Indications and Usage (1.1, 1.2, 1.3)].
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Baricitinib is a substrate of the Pgp, BCRP, OAT3 and MATE2-K transporters, which play roles in drug distribution.
Metabolism – Approximately 6% of the orally administered baricitinib dose is identified as metabolites (three from urine and one from feces), with CYP3A4 identified as the main metabolizing enzyme.
Excretion – Renal elimination is the principal clearance mechanism for baricitinib through filtration and active secretion as baricitinib is identified as a substrate of OAT3, Pgp, BCRP and MATE2-K from in vitro studies.
In clinical pharmacology studies, there were no clinically meaningful changes in the pharmacokinetics (PK) of simvastatin, ethinyl estradiol, or levonorgestrel (CYP3A substrates) when co-administered with baricitinib.
In vitro studies suggest that baricitinib is not an inhibitor of the transporters, P-glycoprotein (Pgp) or Organic Anion Transporting Polypeptide (OATP) 1B1.
In vitro data indicate baricitinib does inhibit organic anionic transporter (OAT) 1, OAT2, OAT3, organic cationic transporter (OCT) 1, OCT2, OATP1B3, Breast Cancer Resistance Protein (BCRP) and Multidrug and Toxic Extrusion Protein (MATE) 1 and MATE2-K, but clinically meaningful changes in the pharmacokinetics of drugs that are substrates for these transporters are unlikely.
Figure 2 Potential for Other Drugs to Influence the PK of Baricitinib In vitro studies suggest that baricitinib is a CYP3A4 substrate.
In clinical pharmacology studies there was no effect on the PK of baricitinib when co-administered with ketoconazole (CYP3A inhibitor).
Adverse reactions
The following clinically significant adverse reactions are described elsewhere in the labeling: Serious Infections [see Warnings and Precautions (5.1)] Mortality [see Warnings and Precautions (5.2)] Malignancy and Lymphoproliferative Disorders [see Warnings and Precautions (5.3)] Major Adverse Cardiovascular Events [see Warnings and Precautions (5.4)] Thrombosis [see Warnings and Precautions (5.5)] Hypersensitivity [see Warnings and Precautions (5.6)] Gastrointestinal Perforations [see Warnings and Precautions (5.7)] Hypoglycemia in Patients with Diabetes [see Warnings and Precautions (5.8)] Laboratory Abnormalities [see Warnings and Precautions (5.9)] Adverse reactions reported in clinical trials (≥1%) are (6.1): Moderately to Severely Active RA: upper respiratory tract infections (URTIs), nausea, herpes simplex, and herpes zoster. COVID-19: increases of liver enzymes, thrombocytosis, creatine phosphokinase increases, neutropenia, deep vein thrombosis, pulmonary embolism, and urinary tract infection (UTI) Severe AA: URTIs, headache, acne, hyperlipidemia, creatine phosphokinase increase, UTI, liver enzyme elevations, folliculitis, fatigue, lower respiratory tract infections, nausea, genital Candida infections, anemia, neutropenia, abdominal pain, herpes zoster, and weight increase.
To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at …
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice. Moderately to Severely Active Rheumatoid Arthritis The safety of OLUMIANT was evaluated in six randomized double-blind placebo-controlled studies (three Phase 2, three Phase 3) and a long-term extension study in subjects with moderately to severely active RA.
Subjects were randomized to placebo (1070 subjects), OLUMIANT 2 mg (479 subjects), or baricitinib 4 mg (997 subjects). Subjects could be switched to baricitinib 4 mg from placebo or OLUMIANT 2 mg from as early as Week 12 depending on the study design. All subjects initially randomized to placebo were switched to baricitinib 4 mg by Week 24.
During the 16-week treatment period, adverse events leading to discontinuation of treatment were reported by 35 subjects (11.4 per 100 patient-years) treated with placebo, 17 subjects (12.1 per 100 patient-years) with OLUMIANT 2 mg, and 40 subjects (13.4 per 100 patient-years) treated with baricitinib 4 mg. During 0 to 52-week exposure, adverse events leading to discontinuation of treatment were reported by 31 subjects (9.2 per 100 patient-years) with OLUMIANT 2 mg, and 92 subjects (10.2 per 100 patient-years) treated with baricitinib 4 mg.
Overall Infections – During the 16-week treatment period, infections were reported by 253 subjects (82.1 per 100 patient-years) treated with placebo, 139 subjects (99.1 per 100 patient-years) treated with OLUMIANT 2 mg, and 298 subjects (100.1 per 100 patient-years) treated with baricitinib 4 mg. During 0 to 52-week exposure, infections were reported by 200 subjects (59.6 per 100 patients-years) treated with OLUMIANT 2 mg, and 500 subjects (55.3 per 100 patient-years) treated with baricitinib 4 mg.
In the 0 to 52-week exposure population, the most commonly reported infections with OLUMIANT were viral upper respiratory tract infection, upper respiratory tract infection, urinary tract infection, and bronchitis. Serious Infections – During the 16-week treatment period, serious infections were reported in 13 subjects (4.2 per 100 patient-years) treated with placebo, 5 subjects (3.6 per 100 patient-years) treated with OLUMIANT 2 mg, and 11 subjects (3.7 per 100 patient-years) treated with baricitinib 4 mg.
During 0 to 52-week exposure, serious infections were reported in 14 subjects (4.2 per 100 patient-years) treated with OLUMIANT 2 mg and 32 subjects (3.5 per 100 patient-years) treated with baricitinib 4 mg. In the 0 to 52-week exposure population, the most commonly reported serious infections with OLUMIANT were pneumonia, herpes zoster, and urinary tract infection [see Warnings and Precautions (5.1)].
Tuberculosis – During the 16-week treatment period, no events of tuberculosis were reported. During 0 to 52-week exposure, events of tuberculosis were reported in 0 subjects treated with OLUMIANT 2 mg and 1 subject (0.1 per 100 patient-years) treated with baricitinib 4 mg [see Warnings and Precautions (5.1)]. Cases of disseminated tuberculosis were also reported.
Opportunistic Infections (excluding tuberculosis) – During the 16-week treatment period, opportunistic infections were reported in 2 subjects (0.6 per 100 patient-years) treated with placebo, 0 subjects treated with OLUMIANT 2 mg and 2 subjects (0.7 per 100 patient-years) treated with baricitinib 4 mg. During 0 to 52-week exposure, opportunistic infections were reported in 1 subject (0.3 per 100 patient-years) treated with OLUMIANT 2 mg and 5 subjects (0.6 per 100 patient-years) treated with baricitinib 4 mg [see Warnings and Precautions (5.1)].
Malignancies During the 16-week treatment period, malignancies excluding non-melanoma skin cancers (NMSC) were reported in 0 subjects treated with placebo, 1 subject (0.7 per 100 patient-years) treated with OLUMIANT 2 mg, and 1 subject (0.3 per 100 patient-years) treated with baricitinib 4 mg. During the 0 to 52-week treatment period, malignancies excluding NMSC were reported in 2 subjects (0.6 per 100 patient-years) treated with OLUMIANT 2 mg and 6 subjects (0.7 per 100 patient-years) treated with baricitinib 4 mg [see Warnings and Precautions (5.3)].
Thrombosis Venous Thrombosis – During the 16-week treatment period, venous thromboses (deep vein thrombosis or pulmonary embolism) were reported in 0 subjects treated with placebo, 0 subjects treated with OLUMIANT 2 mg, and 5 subjects (1.7 per 100 patient-years) treated with baricitinib 4 mg. During the 0 to 52-week treatment period, venous thromboses were reported in 2 subjects (0.6 per 100 patient-years) treated with OLUMIANT 2 mg and 7 subjects (0.8 per 100 patient-years) treated with baricitinib 4 mg.
Arterial Thrombosis – During the 16-week treatment period, arterial thromboses were reported in 1 subject treated with placebo (0.3 per 100 patient-years), 2 subjects (1.4 per 100 patient-years) treated with OLUMIANT 2 mg, and 2 subjects (0.7 per 100 patient-years) treated with baricitinib 4 mg. During the 0 to 52-week treatment period, arterial thromboses were reported in 3 subjects (0.9 per 100 patient-years) treated with OLUMIANT 2 mg and 3 subjects (0.3 per 100 patient-years) treated with baricitinib 4 mg.
Laboratory Abnormalities Neutropenia – During the 16-week treatment period, neutrophil counts below 1000 cells/mm 3 occurred in 0% of subjects treated with placebo, 0.6% of subjects treated with OLUMIANT 2 mg, and 0.3% of subjects treated with baricitinib 4 mg. There were no neutrophil counts below 500 cells/mm 3 observed in any treatment group [see Warnings and Precautions (5.1, 5.9)].
Platelet Elevations – During the 16-week treatment period, increases in platelet counts above 600,000 cells/mm 3 occurred in 1.1% of subjects treated with placebo, 1.1% of subjects treated with OLUMIANT 2 mg, and 2.0% of subjects treated with baricitinib 4 mg. Mean platelet count increased by 3000 cells/mm 3 at 16 weeks in subjects treated with placebo, by 15,000 cells/mm 3 at 16 weeks in subjects treated with OLUMIANT 2 mg and by 23,000 cells/mm 3 in subjects treated with baricitinib 4 mg.
Liver Enzyme Elevations – Events of increases in liver enzymes ≥3 times the ULN were observed in subjects treated with OLUMIANT [see Warnings and Precautions (5.9)]. During the 16-week treatment period, ALT elevations ≥3 times the ULN occurred in 1.0% of subjects treated with placebo, 1.7% of subjects treated with OLUMIANT 2 mg, and 1.4% of subjects treated with baricitinib 4 mg.
During the 16-week treatment period, AST elevations ≥ 3 times the ULN occurred in 0.8% of subjects treated with placebo, 1.3% of subjects treated with OLUMIANT 2 mg, and 0.8% of subjects treated with baricitinib 4 mg. In a phase 3 study of DMARD naive subjects, during the 24-week treatment period, ALT and AST elevations ≥3 times the ULN occurred in 1.9% and 0% of subjects treated with methotrexate monotherapy, 1.9% and 1.3% of subjects treated with baricitinib 4 mg monotherapy, and 4.7% and 1.9% of subjects treated with baricitinib 4 mg plus methotrexate.
Lipid Elevations – In controlled clinical trials, OLUMIANT treatment was associated with dose-related increases in lipid parameters including total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol. Elevations were observed at 12 weeks and remained stable thereafter. During the 12-week treatment period, changes in lipid parameters are summarized below: Mean LDL cholesterol increased by 8 mg/dL in subjects treated with OLUMIANT 2 mg and by 14 mg/dL in subjects treated with baricitinib 4 mg.
Mean HDL cholesterol increased by 7 mg/dL in subjects treated with OLUMIANT 2 mg and by 9 mg/dL in subjects treated with baricitinib 4 mg. The mean LDL/HDL ratio remained stable. Mean triglycerides increased by 7 mg/dL in subjects treated with OLUMIANT 2 mg and by 15 mg/dL in subjects treated with baricitinib 4 mg. [See Warnings and Precautions (5.9)].
Creatine Phosphokinase (CPK) – OLUMIANT treatment was associated with increases in CPK within one week of starting OLUMIANT and plateauing after 8 to 12 weeks. At 16 weeks, the mean change in CPK for OLUMIANT 2 mg and baricitinib 4 mg was 37 IU/L and 52 IU/L, respectively. Creatinine – In controlled clinical trials, dose-related increases in serum creatinine were observed with OLUMIANT treatment.
At 52 weeks, the mean increase in serum creatinine was less than 0.1 mg/dL with baricitinib 4 mg. The clinical significance of the observed serum creatinine increases is unknown. Other Adverse Reactions Other adverse reactions are summarized in Table 8. Table 8: Adverse Reactions Occurring in Greater Than or Equal to 1% of OLUMIANT 2 mg and OLUMIANT 4 mg Treated Subjects in Placebo-Controlled Trials for Moderately to Severely Active Rheumatoid Arthritis a Includes acute sinusitis, acute tonsillitis, chronic tonsillitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinobronchitis, sinusitis, tonsillitis, tracheitis, and upper respiratory tract infection. b Includes eczema herpeticum, genital herpes, herpes simplex, ophthalmic herpes simplex, and oral herpes.
Events Weeks 0-16 Placebo OLUMIANT 2 mg OLUMIANT 4 mg n=1070 (%) n=479 (%) n=997 (%) Upper respiratory tract infections a 11.7 16.3 14.7 Nausea 1.6 2.7 2.8 Herpes simplex b 0.7 0.8 1.8 Herpes zoster 0.4 1.0 1.4 Additional adverse drug reactions occurring in fewer than 1% of subjects: acne. COVID-19 The safety of OLUMIANT was evaluated in two randomized, double-blind, placebo-controlled clinical trials of hospitalized adults with COVID-19 for up to 29 days, in which 1307 subjects received at least one dose of OLUMIANT 4 mg once daily, and 1310 subjects received placebo, for up to 14 days or until hospital discharge, whichever occurred first.
In these studies, prophylaxis for venous thromboembolic event (VTEs) was recommended or required for all subjects unless a major contraindication was noted. Overall, the safety profile observed in subjects with COVID-19 treated with OLUMIANT was consistent with the safety profile in subjects with rheumatoid arthritis. Overall Infections – During the first 29 days of the randomized clinical trials, infections were reported in 194 subjects (14.8%) treated with OLUMIANT 4 mg and by 219 subjects (16.7%) treated with placebo.
The most commonly reported infection with OLUMIANT was pneumonia (3.1%). Serious Infections – During the first 29 days of the randomized clinical trials, serious infections were reported in 98 subjects (7.5%) treated with OLUMIANT 4 mg and 120 subjects (9.2%) treated with placebo. The most commonly reported serious infections with OLUMIANT were COVID-19 pneumonia (2.1%) and septic shock (2.1%).
Opportunistic Infections – During the first 29 days of the randomized clinical trials, opportunistic infections were reported in 12 subjects (0.9%) treated with OLUMIANT 4 mg and 14 subjects (1.1%) treated with placebo. Tuberculosis was reported in 1 subject (0.1%) treated with OLUMIANT 4 mg and 0 subjects treated with placebo.
Venous Thrombosis Events – During the first 29 days of the randomized clinical trials, pulmonary embolism was reported in 20 subjects (1.5%) treated with OLUMIANT 4 mg and 11 subjects (0.8%) treated with placebo. Deep vein thrombosis was reported in 20 subjects (1.5%) treated with OLUMIANT 4 mg and 18 subjects (1.4%) treated with placebo.
Adverse drug reactions in greater than or equal to 1% of subjects in trials for COVID-19 are summarized in Table 9. Table 9: Adverse Reactions That Occurred in Greater Than or Equal to 1% of Subjects Treated with OLUMIANT 4 mg During the First 29 Days in Placebo-Controlled Trials for COVID-19 a As assessed by measured values within the clinical trial database.
Frequencies are based on shifts from pre-treatment to post-treatment (with number at risk as the denominator), except for ALT and AST for which frequencies are based on observed elevation during treatment. b Creatine phosphokinase frequencies presented in the table were available for a single trial (COVID II) in subjects with COVID-19 and do not represent integrated data. Placebo N = 1310 n (%) OLUMIANT 4 mg N = 1307 n (%) ALT ≥3 x ULN a 201 (16.0) 230 (18.1) AST ≥3 x ULN a 117 (9.4) 149 (11.8) Thrombocytosis >600,000 cells/mm 3a 34 (4.6) 59 (7.9) Creatine phosphokinase (CPK) >5 x ULN a, b 38 (4.7) 36 (4.5) Neutropenia <1000 cells/mm 3a 22 (1.8) 26 (2.2) Deep vein thrombosis 18 (1.4) 20 (1.5) Pulmonary embolism 11 (0.8) 20 (1.5) Urinary tract infection 13 (1.0) 19 (1.5) Severe Alopecia Areata Adults with Severe Alopecia Areata The safety of OLUMIANT was evaluated in two placebo-controlled trials in adults with severe alopecia areata [see Clinical Studies (14)].
Subjects were randomized to placebo (371 subjects), OLUMIANT 2 mg (365 subjects), or OLUMIANT 4 mg (540 subjects). Of these, a total of 845 subjects were treated with OLUMIANT for at least 1 year. Table 10 summarizes adverse reactions that occurred at a frequency of at least 1% in subjects treated with OLUMIANT 2 mg once daily or OLUMIANT 4 mg once daily and more frequently than in subjects receiving placebo during the 36-week placebo-controlled period of the severe alopecia areata clinical trials.
Table 10: Adverse Reactions That Occurred in ≥1% of Adults Treated with OLUMIANT 2 mg or OLUMIANT 4 mg in Severe Alopecia Areata Trials a %-study size adjusted percentages. b URTI includes: acute sinusitis, influenza, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection, viral upper respiratory tract infection, viral sinusitis, viral pharyngitis, respiratory tract infection viral, rhinovirus infection and adenoiditis c Acne includes: acne and dermatitis acneiform. d Hyperlipidemia includes: hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, dyslipidemia, lipids increased, low density lipoprotein increased, blood cholesterol increased, and blood triglycerides increased. e UTI includes: cystitis, urinary tract infection, white blood cells urine positive, urinary tract infection bacterial, and pyelonephritis. f Liver enzyme elevations includes: transaminases increased, aspartate aminotransferase increased, alanine aminotransferase increased, hepatic enzyme increased, gamma-glutamyl transferase increased, and hepatic function abnormal. g Folliculitis was most commonly localized in the scalp region associated with hair regrowth h LRTI includes: bronchitis, bronchiolitis, lower respiratory tract infection, pneumonia, COVID-19 pneumonia, and respiratory tract infection. i Genital Candida infections includes: vulvovaginal candidiasis, vulvovaginal mycotic infection, and genital infection fungal. j Neutropenia includes: neutropenia and neutrophil count decreased. k Abdominal pain includes: abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal discomfort. Adverse Reaction Weeks 0-36 Placebo OLUMIANT 2 mg OLUMIANT 4 mg N=371 (%) a N=365 (%) a N=540 (%) a Upper respiratory tract infections b (URTI) 19.9 18.4 21.3 Headache 5.4 5.5
6.6 Acne
6.6 Acne c 2.2 5.8 5.9 Hyperlipidemia d 3.0 3.6 5.9 Blood creatine phosphokinase increased 1.3 0.8 4.3 Urinary tract infections (UTI) e 2.2 3.8 3.7 Liver enzyme elevations f 2.4 1.1 3.0 Folliculitis g 0.8 1.4 2.2 Fatigue 1.1 0.8 2.2 Lower respiratory tract infections (LRTI) h 0.8 2.2 2.0 Nausea 1.6 2.7 2.0 Genital Candida infections i 0.3 2.2 1.3 Anemia 0.3 0.3 1.3 Neutropenia j 0.8 0.3 1.3 Abdominal pain k 2.2 3.8 0.9 Herpes zoster 0.5 1.4 0.9 Weight increased 0.3 1.6 0.9 In subjects treated with any dose of baricitinib, adverse reactions that occurred in fewer than 1% of subjects include arterial thrombosis, B cell lymphoma, lymphopenia, and fungal skin infections. Additional adverse reactions observed after Week 52: venous thromboembolic events (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), and malignancy including non-melanoma skin cancer.
Overall, the adverse reactions observed in subjects with severe alopecia areata treated with OLUMIANT were consistent with the adverse reactions in subjects with moderately to severely active rheumatoid arthritis. Pediatric Subjects 12 Years of Age and Older with Severe Alopecia Areata The safety of OLUMIANT was evaluated in pediatric subjects 12 years of age and older who weigh at least 30 kg with severe alopecia areata in a randomized, double-blind, placebo-controlled clinical trial [see Clinical Studies (14)].
Subjects were randomized to placebo (88 subjects), OLUMIANT 2 mg (83 subjects), or OLUMIANT 4 mg (85 subjects). Overall, the safety profile observed in pediatric subjects 12 years of age and older with severe alopecia areata treated with OLUMIANT is consistent with the safety profile in adults with severe alopecia areata.
In the open-label extension period of this trial, 316 pediatric subjects 12 years of age and older were treated with OLUMIANT 2 mg or 4 mg for at least 1 year and the safety profile remained consistent with that observed in adults with severe AA [see Use in Specific Populations (8.4)].
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of OLUMIANT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Immune System Disorders: Drug hypersensitivity (events such as rash, urticaria, and angioedema have been reported) [see Warnings and Precautions (5.6)].
Metabolism and Nutrition Disorders: Hypoglycemia [see Warnings and Precautions (5.8)].
Adverse reaction frequency tables (US label) US FDA label
| a Includes acute sinusitis, acute tonsillitis, chronic tonsillitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinobronchitis, sinusitis, tonsillitis, tracheitis, and upper respiratory tract infection. | |||
| b Includes eczema herpeticum, genital herpes, herpes simplex, ophthalmic herpes simplex, and oral herpes. | |||
| Events | Weeks 0-16 | ||
| Placebo | OLUMIANT 2 mg | OLUMIANT 4 mg | |
| n=1070 (%) | n=479 (%) | n=997 (%) | |
| Upper respiratory tract infectionsa | 11.7 | 16.3 | 14.7 |
| Nausea | 1.6 | 2.7 | 2.8 |
| Herpes simplexb | 0.7 | 0.8 | 1.8 |
| Herpes zoster | 0.4 | 1.0 | 1.4 |
| a As assessed by measured values within the clinical trial database. Frequencies are based on shifts from pre-treatment to post-treatment (with number at risk as the denominator), except for ALT and AST for which frequencies are based on observed elevation during treatment. | ||
| b Creatine phosphokinase frequencies presented in the table were available for a single trial (COVID II) in subjects with COVID-19 and do not represent integrated data. | ||
| Placebo N = 1310 n (%) | OLUMIANT 4 mg N = 1307 n (%) | |
| ALT ≥3 x ULNa | 201(16.0) | 230 (18.1) |
| AST ≥3 x ULNa | 117 (9.4) | 149 (11.8) |
| Thrombocytosis >600,000 cells/mm3a | 34 (4.6) | 59 (7.9) |
| Creatine phosphokinase (CPK) >5 x ULNa, b | 38 (4.7) | 36 (4.5) |
| Neutropenia <1000 cells/mm3a | 22 (1.8) | 26 (2.2) |
| Deep vein thrombosis | 18 (1.4) | 20 (1.5) |
| Pulmonary embolism | 11 (0.8) | 20 (1.5) |
| Urinary tract infection | 13 (1.0) | 19 (1.5) |
| a %-study size adjusted percentages. | |||
| b URTI includes: acute sinusitis, influenza, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection, viral upper respiratory tract infection, viral sinusitis, viral pharyngitis, respiratory tract infection viral, rhinovirus infection and adenoiditis | |||
| c Acne includes: acne and dermatitis acneiform. | |||
| d Hyperlipidemia includes: hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, dyslipidemia, lipids increased, low density lipoprotein increased, blood cholesterol increased, and blood triglycerides increased. | |||
| e UTI includes: cystitis, urinary tract infection, white blood cells urine positive, urinary tract infection bacterial, and pyelonephritis. | |||
| f Liver enzyme elevations includes: transaminases increased, aspartate aminotransferase increased, alanine aminotransferase increased, hepatic enzyme increased, gamma-glutamyl transferase increased, and hepatic function abnormal. | |||
| g Folliculitis was most commonly localized in the scalp region associated with hair regrowth | |||
| h LRTI includes: bronchitis, bronchiolitis, lower respiratory tract infection, pneumonia, COVID-19 pneumonia, and respiratory tract infection. | |||
| i Genital Candida infections includes: vulvovaginal candidiasis, vulvovaginal mycotic infection, and genital infection fungal. | |||
| j Neutropenia includes: neutropenia and neutrophil count decreased. | |||
| k Abdominal pain includes: abdominal pain, abdominal pain lower, abdominal pain upper, and abdominal discomfort. | |||
| Adverse Reaction | Weeks 0-36 | ||
| Placebo | OLUMIANT 2 mg | OLUMIANT 4 mg | |
| N=371 (%) a | N=365 (%) a | N=540 (%) a | |
| Upper respiratory tract infectionsb (URTI) | 19.9 | 18.4 | 21.3 |
| Headache | 5.4 | 5.5 | 6.6 |
| Acnec | 2.2 | 5.8 | 5.9 |
| Hyperlipidemiad | 3.0 | 3.6 | 5.9 |
| Blood creatine phosphokinase increased | 1.3 | 0.8 | 4.3 |
| Urinary tract infections (UTI)e | 2.2 | 3.8 | 3.7 |
| Liver enzyme elevationsf | 2.4 | 1.1 | 3.0 |
| Folliculitisg | 0.8 | 1.4 | 2.2 |
| Fatigue | 1.1 | 0.8 | 2.2 |
| Lower respiratory tract infections (LRTI)h | 0.8 | 2.2 | 2.0 |
| Nausea | 1.6 | 2.7 | 2.0 |
| Genital Candida infectionsi | 0.3 | 2.2 | 1.3 |
| Anemia | 0.3 | 0.3 | 1.3 |
| Neutropeniaj | 0.8 | 0.3 | 1.3 |
| Abdominal paink | 2.2 | 3.8 | 0.9 |
| Herpes zoster | 0.5 | 1.4 | 0.9 |
| Weight increased | 0.3 | 1.6 | 0.9 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to OLUMIANT during pregnancy. Healthcare providers may encourage pregnant women exposed to OLUMIANT to enroll in the OLUMIANT pregnancy registry by calling 1-800-284-1695 or by visiting https://pregnancyregistry.lilly.com.
Risk Summary Based on the findings from animal reproduction studies, OLUMIANT may cause fetal harm during pregnancy. Available data from clinical trials and postmarketing case reports with OLUMIANT exposure in pregnancy are insufficient to inform a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes.
There are no human data on chronic baricitinib exposure throughout pregnancy. There are risks to the mother and the fetus associated with rheumatoid arthritis in pregnancy (see Clinical Considerations). Consider the risks and benefits with chronic use of OLUMIANT during pregnancy. In animal embryo-fetal development studies, oral baricitinib administration to pregnant rats and rabbits at exposures equal to and greater than approximately 11 and 46 times the maximum recommended human dose (MRHD) of 4 mg/day, respectively, resulted in reduced fetal body weights, increased embryolethality (rabbits only), and dose-related increases in skeletal malformations.
No developmental toxicity was observed in pregnant rats and rabbits treated with oral baricitinib during organogenesis at approximately 2 and 7 times the exposure at the MRHD, respectively. In a pre- and post-natal development study in pregnant female rats, oral baricitinib administration at exposures approximately 24 times the MRHD resulted in reduction in pup viability (increased incidence of stillborn pups and early neonatal deaths), decreased fetal birth weight, reduced fetal body weight gain, decreased cytotoxic T cells on post-natal day (PND) 35 with evidence of recovery by PND 65, and developmental delays that might be attributable to decreased body weight gain.
No developmental toxicity was observed at an exposure approximately 5 times the exposure at the MRHD (see Data). The background risks of major birth defects and miscarriage for the indicated population(s) are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Published data suggest that increased disease activity is associated with the risk of developing adverse pregnancy outcomes in women with rheumatoid arthritis. Adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2500 g) infants, and small for gestational age at birth.
Data Animal Data In an embryofetal development study in pregnant rats, dosed orally during the period of organogenesis from gestation days 6 to 17, baricitinib was teratogenic (skeletal malformations that consisted of bent limb bones and rib anomalies) at exposures equal to or greater than approximately 11 times the MRHD (on an AUC basis at maternal oral doses of 10 mg/kg/day and higher). No developmental toxicity was observed in rats at an exposure approximately 2 times the MRHD (on an AUC basis at a maternal oral dose of 2 mg/kg/day).
In an embryofetal development study in pregnant rabbits, dosed orally during the period of organogenesis from gestation days 7 to 20, embryolethality, decreased fetal body weights, and skeletal malformations (rib anomalies) were observed in the presence of maternal toxicity at an exposure approximately 46 times the MRHD (on an AUC basis at a maternal oral dose of 30 mg/kg/day). Embryolethality consisted of increased post-implantation loss that was due to elevated incidences of both early and late resorptions.
No developmental toxicity was observed in rabbits at an exposure approximately 7 times the MRHD (on an AUC basis at a maternal oral dose of 10 mg/kg/day). In a pre- and post-natal development study in pregnant female rats dosed orally from gestation day 6 through lactation day 20, adverse findings observed in pups included decreased survival from birth to post-natal day 4 (due to increased stillbirths and early neonatal deaths), decreased birth weight, decreased body weight gain during the pre-weaning phase, increased incidence of malrotated forelimbs during the pre-weaning phase, and decreased cytotoxic T cells on PND 35 with recovery by PND 65 at exposures approximately 24 times the MRHD (on an AUC basis at a maternal oral dose of 25 mg/kg/day).
Developmental delays (that may be secondary to decreased body weight gain) were observed in males and females at exposures approximately 24 times the MRHD (on an AUC basis at a maternal oral dose of 25 mg/kg/day). These findings included decreased forelimb and hindlimb grip strengths, and delayed mean age of sexual maturity.
No developmental toxicity was observed in rats at an exposure approximately 5 times the MRHD (on an AUC basis at a maternal oral dose of 5 mg/kg/day).
Mechanism of action
12.1 Mechanism of Action Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression.
Baricitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs. JAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2). In cell-free isolated enzyme assays, baricitinib had greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3.
In human leukocytes, baricitinib inhibited cytokine induced STAT phosphorylation mediated by JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, or JAK2/TYK2 with comparable potencies. However, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Baricitinib inhibition of IL-6 induced STAT3 phosphorylation – Baricitinib administration resulted in a dose dependent inhibition of IL-6 induced STAT3 phosphorylation in whole blood from healthy subjects with maximal inhibition observed approximately 1 hour after dosing, which returned to near baseline by 24 hours. Similar levels of inhibition were observed using either IL-6 or TPO as the stimulus.
Immunoglobulins – Mean serum IgG, IgM, and IgA values decreased by 12 weeks after starting treatment with OLUMIANT, and remained stable through at least 52 weeks. For most subjects, changes in immunoglobulins occurred within the normal reference range. C-reactive protein – In subjects with rheumatoid arthritis, decreases in serum C-reactive protein (CRP) were observed as early as one week after starting treatment with OLUMIANT and were maintained throughout dosing.
Cardiac Electrophysiology – At a dose 10 times the maximum recommended dose, baricitinib does not prolong the QT interval to any clinically relevant extent.
Pharmacokinetics
Elimination half-life in subjects with moderately to severely active rheumatoid arthritis and severe alopecia areata is approximately 12 to 16 hours.
COVID-19: The total body clearance and half-life of baricitinib is 14.2 L/h and 10.8 hours, respectively, in subjects with COVID-19 who are intubated and have baricitinib administered via NG or OG tube.
Excretion – Renal elimination is the principal clearance mechanism for baricitinib through filtration and active secretion as baricitinib is identified as a substrate of OAT3, Pgp, BCRP and MATE2-K from in vitro studies.
In a clinical pharmacology study, approximately 75% of the administered dose was eliminated in the urine, while about 20% of the dose was eliminated in the feces.
Baricitinib was excreted predominantly as unchanged drug in urine (69%) and feces (15%).
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Following oral administration of OLUMIANT, peak plasma concentrations are reached approximately at 1 hour. A dose-proportional increase in systemic exposure was observed in the therapeutic dose range. The pharmacokinetics of baricitinib do not change over time. Steady-state concentrations are achieved in 2 to 3 days with minimal accumulation after once-daily administration.
Absorption – The absolute bioavailability of baricitinib is approximately 80%. An assessment of food effects in healthy subjects showed that a high-fat meal decreased the mean AUC and C max of baricitinib by approximately 11% and 18%, respectively, and delayed the t max by 0.5 hours. Administration with meals is not associated with a clinically relevant effect on exposure.
In clinical studies, OLUMIANT was administered without regard to meals. Distribution – After intravenous administration, the volume of distribution is 76 L, indicating distribution of baricitinib into tissues. Baricitinib is approximately 50% bound to plasma proteins and 45% bound to serum proteins. Baricitinib is a substrate of the Pgp, BCRP, OAT3 and MATE2-K transporters, which play roles in drug distribution.
Elimination Moderately to Severely Active Rheumatoid Arthritis and Severe Alopecia Areata: The total body clearance of baricitinib is 8.9 L/h in subjects with moderately to severely active rheumatoid arthritis and 11 L/h in subjects with severe alopecia areata. Elimination half-life in subjects with moderately to severely active rheumatoid arthritis and severe alopecia areata is approximately 12 to 16 hours.
COVID-19: The total body clearance and half-life of baricitinib is 14.2 L/h and 10.8 hours, respectively, in subjects with COVID-19 who are intubated and have baricitinib administered via NG or OG tube. Metabolism – Approximately 6% of the orally administered baricitinib dose is identified as metabolites (three from urine and one from feces), with CYP3A4 identified as the main metabolizing enzyme.
No metabolites of baricitinib were quantifiable in plasma. Excretion – Renal elimination is the principal clearance mechanism for baricitinib through filtration and active secretion as baricitinib is identified as a substrate of OAT3, Pgp, BCRP and MATE2-K from in vitro studies. In a clinical pharmacology study, approximately 75% of the administered dose was eliminated in the urine, while about 20% of the dose was eliminated in the feces.
Baricitinib was excreted predominantly as unchanged drug in urine (69%) and feces (15%). Specific Populations Effects of Body Weight, Gender, Race, and Age Body weight, gender, race, ethnicity, and age did not have a clinically relevant effect on the PK (AUC and C max) of baricitinib (Figure 1). The mean effects of intrinsic factors on PK parameters (AUC and C max) were generally within the inter-subject PK variability of baricitinib.
The inter-subject variabilities (% coefficients of variation) in AUC and C max of baricitinib are approximately 41% and 22%, respectively, in subjects with rheumatoid arthritis [see Use in Specific Populations (8.5)]. Pediatric Patients 12 Years of Age and Older with Severe Alopecia Areata: The PK exposure of baricitinib is similar for pediatric subjects 12 years of age and older and adults with severe alopecia areata upon receiving a 2 mg or 4 mg dose.
Patients with Renal Impairment Baricitinib systemic exposure in AUC was increased by 1.41-, 2.22-, 4.05- and 2.41-fold for mild (60 – <90 mL/minute/1.73 m²), moderate (30 – <60 mL/min/1.73 m²), severe (<30 mL/minute/1.73 m²), and ESRD (with hemodialysis) renal impairment sub-groups, respectively, compared to subjects with normal renal function. The corresponding values for increase in C max were 1.16-, 1.46-, 1.40- and 0.88-fold, respectively (Figure 1) [see Use in Specific Populations (8.7)].
Patients with Hepatic Impairment Baricitinib systemic exposure and C max increased by 1.19- and 1.08-fold for the moderate (Child-Pugh B) hepatic impairment group, respectively, compared to subjects with normal hepatic function (Figure 1) [see Use in Specific Populations (8.6)]. Figure 1: Impact of Intrinsic Factors on OLUMIANT Pharmacokinetics a, b a Reference values for weight, age, gender, and race comparisons are 70 kg, 54 years, male, and white, respectively; reference groups for renal and hepatic impairment are subjects with normal renal and hepatic function, respectively. b Effects of renal and hepatic impairment on baricitinib exposure were summarized from dedicated renal and hepatic impairment studies, respectively.
Effects of other intrinsic factors on baricitinib exposure were summarized from population PK analysis. c The recommended dose for subjects with COVID-19 and severe renal impairment (eGFR 15 - <30 mL/min/1.73 m²) is 1 mg once daily. OLUMIANT is not recommended for use in subjects with COVID-19 who are on dialysis, have end-stage renal disease (ESRD), or acute kidney injury (eGFR <15 mL/min/1.73 m²). [see Dosage and Administration (2.6)] Figure 1 Drug Interactions Potential for Baricitinib to Influence the PK of Other Drugs In vitro, baricitinib did not significantly inhibit or induce the activity of cytochrome P450 enzymes (CYPs 3A, 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6).
In clinical pharmacology studies, there were no clinically meaningful changes in the pharmacokinetics (PK) of simvastatin, ethinyl estradiol, or levonorgestrel (CYP3A substrates) when co-administered with baricitinib. In vitro studies suggest that baricitinib is not an inhibitor of the transporters, P-glycoprotein (Pgp) or Organic Anion Transporting Polypeptide (OATP) 1B1.
In vitro data indicate baricitinib does inhibit organic anionic transporter (OAT) 1, OAT2, OAT3, organic cationic transporter (OCT) 1, OCT2, OATP1B3, Breast Cancer Resistance Protein (BCRP) and Multidrug and Toxic Extrusion Protein (MATE) 1 and MATE2-K, but clinically meaningful changes in the pharmacokinetics of drugs that are substrates for these transporters are unlikely. In clinical pharmacology studies there were no clinically meaningful effects on the PK of digoxin (Pgp substrate) or methotrexate (substrate of several transporters) when co-administered with baricitinib.
Exposure changes of drugs following co-administration with baricitinib are shown in Figure 2. Figure 2: Impact of OLUMIANT on the Pharmacokinetics of Other Drugs a a Reference group is administration of concomitant drug alone. Figure 2 Potential for Other Drugs to Influence the PK of Baricitinib In vitro studies suggest that baricitinib is a CYP3A4 substrate.
In clinical pharmacology studies there was no effect on the PK of baricitinib when co-administered with ketoconazole (CYP3A inhibitor). There were no clinically meaningful changes in the PK of baricitinib when co-administered with fluconazole (CYP3A/CYP2C19/CYP2C9 inhibitor) or rifampin (CYP3A inducer). In vitro studies suggest that baricitinib is a substrate for OAT3, Pgp, BCRP and MATE2-K.
In a clinical study, probenecid administration (strong OAT3 inhibitor) resulted in an approximately 2-fold increase in baricitinib AUC 0-∞ with no effect on C max and t max [see Dosage and Administration (2.7) and Drug Interactions (7.1)]. However, simulations with diclofenac and ibuprofen (OAT3 inhibitors with less inhibition potential) predicted minimal effect on the PK of baricitinib.
In clinical pharmacology studies there was no clinically meaningful effect on the PK of baricitinib when co-administered with cyclosporine (Pgp and BCRP inhibitor). Co-administration with methotrexate (substrate of several transporters) did not have a clinically meaningful effect on the PK of baricitinib. Exposure changes of baricitinib following co-administration with CYP inhibitors or inducers, transporter inhibitors, as well as methotrexate and the proton pump inhibitor, omeprazole, are shown in Figure 3.
Figure 3: Impact of Other Drugs on the Pharmacokinetics of OLUMIANT b a Values are based on simulated studies. b Reference group is administration of baricitinib alone. Figure 3
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Olumiant · Eli Lilly and Company [US FDA-approved label, version 32, October 9, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=866e9f35-9035-4581-a4b1-75a621ab55cf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .